This site is intended for U.S. healthcare professionals only.

References

References:

  1. Ensacove™ (ensartinib) Prescribing Information. Miami, FL: Xcovery Holdings, Inc. 2024.
  2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for Non-Small Cell Lung Cancer V.8.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed September 12, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  3. Horn L, Wang Z, Wu G, et al. Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase−positive non-small cell lung cancer: a randomized clinical trial. JAMA Oncol. 2021;7(11):1617-1625.
  4. Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056‑1064.
  5. Peng L, Zhu L, Sun Y, et al. Targeting ALK rearrangements in NSCLC: current state of the art. Front Onc. 2022;12:1‑13.
  6. Chia PL, Mitchell P, Dobrovic A, John T. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol. 2014;6:423‑432.
  7. Hofman P. ALK in non-small cell lung cancer (NSCLC) pathobiology epidemiology, detection from tumor tissue and algorithm diagnosis in a daily practice. Cancers. 2017;9(107):1‑16.
  8. American Cancer Society. What is lung cancer? Accessed: July 29, 2025. Available at: https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html.
  9. Lin HM, Wu Y, Yin Y, et al. Real-world ALK testing trends in patients with advanced non–small-cell lung cancer in the United States. Clin Lung Cancer. 2023;24(1):e39‑e49.
  10. Eldridge L. What is ALK‑positive lung cancer. Accessed August 19, 2025. Available at https://www.verywellhealth.com/alk-positive-lung-cancer-definition-and-treatment-2248944.
  11. Tang W, Lei Y, Su J, et al. TNM stages inversely correlate with the age at diagnosis in ALK-positive lung cancer. Transl Lung Cancer Res. 2019;8(2):144‑154.
  12. Ou S-H I, Bartlett CH, Mino-Kenudson M, et al. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. The Oncologist. 2012;17:1351‑1375.
  13. Ganti AK, Lin C-W, Yang E, et al. Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non–small cell lung cancer. J Manag Care Spec Pharm. 2022;28(3):305-314.
  14. Wu Y-L, Kim HR, Soo RA, et al. First-line lorlatinib versus crizotinib in Asian patients with advanced ALK-positive NSCLC: Five-year outcomes from the CROWN study. J Thoracic Oncology. 2025;20(7):955‑968.
  15. Aldea M, Besse B, Hendricks LEL. ALK inhibitors in ALK-positive NSCLC with central nervous system metastases. Eur Oncol and Haematol. 2020;16(1): 18-21.
  16. Griesinger F, Roeper J, Potttgen C, et al. Brain metastases in ALK-positive NSCLC–time to adjust current treatment algorithms. Oncotarget. 2018;9(80):35181-35194.
  17. Rangachari D, Yamaguchi N, VanderLaan PA, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 2015;88(1):108‑111.
  18. Schoenmaekers JJAO, Paats MS, Dingemans A-MC, Hendriks LEL. Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when? Transl Lung Cancer Res. 2020;9(6):2599-2617.

1L, first line; ALK, anaplastic lymphoma kinase; NSCLC, non-small cell lung cancer; tyrosine kinase inhibitor; FDA, Food and Drug Administration.